11 results about "Digestive Tumor" patented technology

The application discloses a kind of gene markers in esophagus, stomach, intestine multiple cancer early screening application, early screening model construction method and detection device, belong to the early non-invasive detection technical field of digestive tract tumor.It establishes a new type of multiple cancer screening system by analyzing the whole genome characteristics of circulating free DNA in peripheral blood.Based on low-depth whole genome sequencing data, three dimensions of molecular markers are detected: genome copy number variation pattern, DNA fragment distribution characteristics of specific length and epigenetic signals of transcription initiation region.Advanced converter neural network architecture is used, and the model can efficiently capture the complex feature correlation in the whole genome range through its unique self-attention mechanism.The model design specially considers the particularity of genomic data, and introduces an adaptive position coding system to accurately reflect the spatial distribution relationship of DNA fragments on the chromosome.The system can still maintain excellent detection performance at very low sequencing depth.

The application discloses a molecular marker and MRI image fusion tumor early detection method and system, first collects serum molecular marker detection data and multi-sequence MRI image data of a digestive tract tumor screening object, constructs a molecular feature vector and extracts high-dimensional MRI image features respectively; a tumor prior probability is calculated through a molecular pre-screening deep neural network, and an adaptive spatial attention guide weight is generated; the weight is weighted and fused with the MRI image features to realize fine feature enhancement of a high-risk area and accurate lesion detection; based on a Bayesian evidence fusion reasoning framework, molecular detection evidence and image detection evidence are combined to update a posterior probability, and finally, a lesion positioning, detection confidence and visual detection report are output. The application realizes efficient complementation of molecular evidence and image evidence, greatly improves the accuracy, sensitivity and specificity of early detection of digestive tract tumors, and is suitable for non-invasive accurate screening of high-risk groups in clinical practice.

The invention relates to the technical field of medical instruments, and particularly discloses an intelligent navigation and real-time monitoring system for a minimally invasive surgery under a digestive tract tumor endoscope, which is characterized in that a real-time endoscope video sequence and intraoperative high-resolution image data are synchronously acquired; processing the video sequence to construct and update in real time an initial three-dimensional expression reflecting the spatial topology of the surgical region; performing spatial correlation registration on the intra-operative image data and the corresponding video frame, and calculating the position and direction of the intra-operative image data relative to the initial three-dimensional expression; according to the spatial relationship, performing dynamic fusion weight-based adaptive fusion and optimization on anatomical details contained in the intraoperative image and the initial three-dimensional expression to generate a composite data expression named as an incremental dynamic navigation structure; on the basis of the structure, augmented reality navigation information which is matched with the current endoscope visual field and comprises virtual perspective superposition of the tumor and the blood vessel network is calculated and generated in real time; according to the invention, the accuracy, robustness and safety of navigation in a complex dynamic operation environment are improved.

The application provides a microorganism marker group, a tumor prognosis prediction model establishment method and application thereof, and relates to the technical field of biomedicine. The microorganism marker group is related to a preset total survival time. Based on the microorganism marker group obtained from tumor tissues and paracancer normal tissues, the prognosis prediction accuracy and sensitivity of a digestive tract tumor can be effectively improved.

The invention discloses a digestive tract tumor recognition method and system and a medium, and relates to the technical field of medical image processing.According to the method, the step length and the layer number of Z-axis sampling are dynamically optimized according to the calculated tangent plane inclination angle, and on the premise that it is guaranteed that a complete glandular tube three-dimensional structure is collected, the number of layers of Z-axis sampling is increased; the problems of local defocus and form distortion caused by tissue beveling are effectively avoided, and the definition of the image and the interlayer registration precision are remarkably improved. In addition, a virtual vertical section reconstruction strategy is introduced, geometric deformation can be corrected in a three-dimensional voxel space, an observation view meeting a standard anatomical view angle is provided, and therefore interference of film production artifacts on diagnosis is eliminated. And through distinguishing the mucous membrane layer and the non-mucous membrane layer and applying a differentiated scanning strategy, while the data quality of a key region is improved, the scanning time and data redundancy of a non-diagnosis region are greatly reduced, dual optimization of scanning precision and efficiency is realized, and the accuracy and robustness of automatic recognition of digestive tract tumors are remarkably improved.

This application relates to the fields of bioinformatics and medical big data technology, specifically disclosing a digestive tumor risk assessment system based on multi-omics data. The system includes: a multi-source heterogeneous data acquisition terminal, a data standardization preprocessing module, a broad-spectrum digestive system risk assessment engine, an organ-specific feature decoupling module, a multimodal cross-omics fusion reasoning module, and a clinical decision support and early warning terminal. This solution simultaneously acquires ctDNA methylation, serum indicators, and clinical phenotype data, uses the assessment engine to evaluate overall risk, and extracts tissue-specific features through methylation map comparison. Combined with a dynamic weight allocation model, it outputs the targeted risk probabilities for the esophagus, stomach, and colorectal region. This application improves screening sensitivity through multi-dimensional data fusion, solves the problems of reliance on a single data source and inability to locate lesions, and achieves accurate organ-specific analysis and early warning.

The present application relates to the technical field of image semantic segmentation, in particular to a digestive tract tumor lesion image segmentation method and system based on multi-modal fusion technology, comprising the following steps: collecting CT and EUS sequences to generate an organ surface three-dimensional triangular mesh model, mapping anatomical markers and constructing a dual-mode lumen manifold surface geodesic distance topological atlas, calculating the connection edge difference and the total amount of elastic potential energy, and generating a digestive tract tumor lesion pixel-level segmentation mask. In the present application, the organ physical form is restored by constructing a covering tube wall triangular mesh reducer, the path length is accurately quantified by using the manifold surface geodesic distance instead of the straight line distance, the potential energy gradient is calculated to drive the nodes to converge in the energy descent direction, the non-rigid mapping field conforming to the anatomical constraint is generated to offset the endoscope compression distortion, the EUS texture is accurately mapped to the CT coordinate system under the premise of maintaining the topological integrity, the multi-modal feature deep fusion is realized, and the soft tissue lesion segmentation accuracy is improved.

The application discloses a polypeptide specifically binding to Sestrin2 protein and application thereof in treatment of digestive tract cancer. Specifically disclosed is a STAMBPL1 polypeptide with an amino acid sequence of SEQ ID No. 1, which is a polypeptide specifically binding to Sestrin2 protein and can block the interaction between Sestrin2 and STAMBPL1 through competitive binding. The application further provides a chimeric peptide tat-STAMBPL1 with cell permeability comprising the STAMBPL1 polypeptide and a cell-penetrating peptide. The polypeptide and the chimeric peptide of the application have high affinity, clear target, target the Sestrin2 / STAMBPL1 interaction site, and can effectively inhibit tumor (especially digestive tract tumor) formation. The application further provides an anti-tumor drug comprising the STAMBPL1 polypeptide and / or the chimeric peptide tat-STAMBPL1.

The invention discloses an oral in-situ assembled drug loading system and application thereof. The oral in-situ assembled drug loading system comprises a component A and a component B which can be separately administrated, the component A comprises hyaluronic acid which is modified by protocatechuic acid and coats a platelet membrane; the component B comprises hyaluronic acid which is modified by a thiourea group and is loaded with an STING agonist and traditional Chinese medicine polysaccharide. During administration, the component A is orally taken first, then the component B is orally taken after 2-10 minutes, and the component A and the component B are subjected to in-situ cross-linking gel formation through a catechol-thiourea specific coupling reaction in a high reactive oxygen inflammation environment of a postoperative wound surface of a digestive tract tumor. Wherein the STING agonist MSA-2 and the traditional Chinese medicine polysaccharide lentinan (LNT) form a supramolecular compound; the LNT can also prolong an STING signal activated by MSA-2 by depolymerizing microtubulin to generate a synergistic immune effect. The oral gel preparation has the advantages of being convenient to take, accurate in targeting, controllable in gelling, synergistic and the like, and shows a relatively high clinical transformation value in the fields of digestive tract tumor immune regulation, combined treatment and the like.

The invention discloses an intelligent processing method and equipment based on digestive tract tumor images, and relates to the technical field of medical image processing. The method comprises the following steps: acquiring a digestive tract tumor image; preprocessing the digestive tract tumor image; performing data acquisition on the preprocessed digestive tract tumor image to obtain image parameter data; analyzing an image abnormal condition according to the image parameter data; and displaying an abnormal region in the alimentary canal tumor image according to the image abnormal condition. The abnormal condition of the image is analyzed according to the image parameter data, so that the abnormal area in the alimentary canal tumor image is displayed according to the abnormal condition of the image, the tumor image is accurately recognized and displayed, the effect of accurately recognizing the tumor image is achieved, and the accuracy of the recognition result is improved. The problem that in the prior art, it is difficult to accurately recognize tumor images is solved.

The invention belongs to the technical field of medicines, and in particular relates to an application of apiose-platycodin D3 (Deapiose-platycodin D3, the molecular formula of which is C58H94O29, the molecular weight of which is 1255.36 and the CAS number of which is 67884-05-3) in preparation of a medicine for treating gastrointestinal tumors. Through cell proliferation experiments and clone formation experiments, it is verified for the first time that apiose platycodin D3 can effectively inhibit growth of human esophageal cancer, colorectal cancer and gastric cancer cells. The invention provides a new candidate drug and basis for clinical treatment and prevention of gastrointestinal tumors.